What You Should Know

  • To unpack what the ASCENT-03 results really mean, we turned to one of the physicians who helped generate the data.
  • Dr. Kevin Punie discusses why, in his view, first-line use of sacituzumab govitecan makes clinical sense.

Since the phase 3 ASCENT-03 data were first presented at the October 2025 ESMO Congress, a growing groundswell has begun to build among breast oncologists around the use of sacituzumab govitecan (Trodelvy) as a first-line option for patients with metastatic triple-negative breast cancer. The study’s results have intensified conversations not about whether the drug outperforms standard chemotherapy—but whether clinicians are ready to move it earlier in the treatment sequence. As the data continue to be digested, the central question is: what will it take to make first-line use routine in appropriate patients?

The phase 3 study evaluated whether the anti–TROP2 antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) should be used upfront rather than reserved for later lines. According to Dr. Kevin Punie of University Hospitals Leuven, one of the study’s investigators, the results are increasingly difficult to ignore.

Superior Progression-Free Survival

ASCENT-03 demonstrated a clear progression-free survival (PFS) advantage when sacituzumab govitecan was used in the first-line setting.

  • Median PFS: 9.7 months with sacituzumab govitecan vs. 6.9 months with chemotherapy

Dr. Punie explained that the trial was intentionally designed to answer a clinically relevant question. “In ASCENT-03, we tried to answer whether first-line anti–TROP2 ADC works better than second-line,” he said, noting that crossover to sacituzumab govitecan was incorporated so most patients in the control arm received the drug later.

Importantly, even with crossover, the benefit persisted. “The PFS2 analyses that show improvement for sacituzumab govitecan in first and second line is actually quite reassuring and important,” he said.

Why Timing Matters

While overall survival data are still maturing, Dr. Punie emphasized a key practical reality: up to half of patients with metastatic TNBC in real-world settings never receive second-line therapy.

“This is a very aggressive disease,” he said. “Not every patient makes it to second and certainly not to third line.”

That reality strengthens the argument for using the most effective therapy first. “It works better and longer than chemotherapy,” Dr. Punie said. “So it’s always the most logical scenario to position the treatment that has the highest likelihood to respond—or the longest duration of response—upfront.”

Which Patients Benefit Most?

Dr. Punie acknowledged that there may be select patients—such as those with late relapse or minimal, asymptomatic disease—where sequencing decisions remain nuanced. However, he stressed that these cases represent a minority.

For patients with bulky disease, short disease-free intervals, or those at risk of attrition, he believes the evidence now supports earlier use.

“For most patients,” he said, “positioning the anti–TROP2 ADC in first line is better.”

As the oncology community awaits mature overall survival data, ASCENT-03 has already shifted the conversation—moving sacituzumab govitecan from a later-line option to a compelling frontline standard for many patients with metastatic TNBC.